Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with cystic fibrosis (CF).


Options:
A: Arm Label: VX-661/Ivacaftor combination; Type: EXPERIMENTAL; Interventions: Drug: VX-661/Ivacaftor, Drug: Ivacaftor, Drug: Placebo matched to Ivacaftor | Arm Label: Ivacaftor monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo matched to VX-661/ ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to VX-661/ ivacaftor, Drug: Placebo matched to Ivacaftor | Intervention Type: DRUG; Name: VX-661/Ivacaftor; Assigned to Arm(s): VX-661/Ivacaftor combination | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor monotherapy, VX-661/Ivacaftor combination | Intervention Type: DRUG; Name: Placebo matched to VX-661/ ivacaftor; Assigned to Arm(s): Ivacaftor monotherapy, Placebo | Intervention Type: DRUG; Name: Placebo matched to Ivacaftor; Assigned to Arm(s): Placebo, VX-661/Ivacaftor combination
B: Arm Label: JBT101 (lenabasum) 1 mg; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: JBT-101 (lenabasum) 5 mg; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: JBT-101 (lenabasum) 20 mg QD; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: JBT-101 (lenabasum) 20 mg BID; Type: EXPERIMENTAL; Interventions: Drug: JBT-101 (lenabasum) | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: JBT-101 (lenabasum); Assigned to Arm(s): JBT-101 (lenabasum) 20 mg BID, JBT-101 (lenabasum) 20 mg QD, JBT-101 (lenabasum) 5 mg, JBT101 (lenabasum) 1 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Placebo BID
C: Arm Label: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA, VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-445/TEZ/IVA TC
D: Arm Label: Control: IVA or TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: IVA, Drug: TEZ/IVA | Arm Label: TC: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): TC: ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Control: IVA or TEZ/IVA, TC: ELX/TEZ/IVA | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): Control: IVA or TEZ/IVA

Answer: B